FDA Phasing Out Compounded GLP-1 Medications
By the end of May 2025, compounding pharmacies will no longer be permitted to produce GLP-1 medications such as semaglutide (Ozempic, Wegovy). The FDA is ending its temporary allowance for compounded versions now that the national drug shortage has been resolved. During a period of high demand and limited supply, the FDA allowed pharmacies to compound GLP-1s to help patients maintain access while manufacturers scaled up production. With the shortage officially resolved, that allowance is being phased out.
Compounded medications are custom-prepared and not FDA-approved. While often helpful, they may vary in potency and formulation. Most compounded GLP-1s were paid for in cash and are often prescribed outside of traditional clinical settings, such as weight loss clinics or telehealth platforms. Costs typically ranged from $200 to $500 per month. With compounded options going away, members may have more questions about coverage and cost, especially as they seek insurance-covered alternatives.
(The information provided is for educational purposes and should not be used during any medical emergency or for the diagnosis or treatment of any conditions. Consult with your health care provider for diagnosis and treatment of all medical conditions. Call 911 for all medical emergencies.)